Semaglutide patent expiry in India enables low-cost domestic drug launches and partnerships Prices dropped from over Rs 2,000 to as low as Rs 325 weekly, reducing monthly costs Dr Reddys, Glenmark, Natco, and Alkem launched affordable semaglutide versions with approvals
